Scinovex
article Open AccessTop 1% cited

Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results

Movement Disorders · 2008 · Vol. 23(15) · pp. 2129–2170
Christopher G. GoetzBarbara C. TilleyStephanie R. ShaftmanGlenn T. StebbinsStanley FahnPablo Martínez‐MartínWerner PoeweCristina SampaioMatthew B. SternRichard DodelBruno DuboisRobert G. HollowayJoseph JankovicJaime KulisevskyAnthony E. LangAndrew J. LeesSue E. LeurgansPeter A. LeWittDavid L. NyenhuisC. Warren OlanowOlivier RascolAnette SchragJeanne A. TeresiJacobus J. van HiltenNancy R. LaPelle

Abstract

We present a clinimetric assessment of the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The MDS-UDPRS Task Force revised and expanded the UPDRS using recommendations from a published critique. The MDS-UPDRS has four parts, namely, I: Non-motor Experiences of Daily Living; II: Motor Experiences of Daily Living; III: Motor Examination; IV: Motor Complications. Twenty questions are completed by the patient/caregiver. Item-specific instructions and an appendix of complementary additional scales are provided. Movement disorder specialists and study coordinators administered the UPDRS (55 items) and MDS-UPDRS (65 items) to 877 English speaking (78% non-Latino Caucasian) patients with Parkinson's disease from 39 sites. We compared the two scales using correlative techniques and factor analysis. The MDS-UPDRS showed high internal consistency (Cronbach's alpha = 0.79-0.93 across parts) and correlated with the original UPDRS (rho = 0.96). MDS-UPDRS across-part correlations ranged from 0.22 to 0.66. Reliable factor structures for each part were obtained (comparative fit index > 0.90 for each part), which support the use of sum scores for each part in preference to a total score of all parts. The combined clinimetric results of this study support the validity of the MDS-UPDRS for rating PD.

Parkinson's Disease Mechanisms and TreatmentsNeurological disorders and treatmentsAutism Spectrum Disorder ResearchRating scaleCronbach's alphaPsychologyMovement disordersPhysical medicine and rehabilitationPhysical therapyParkinson's diseaseActivities of daily livingPsychometricsDisease

MeSH terms

AdultAgedAged, 80 and overDisability EvaluationFactor Analysis, StatisticalFemaleHumansMaleMiddle AgedMovement DisordersNeurologic ExaminationParkinson DiseaseSeverity of Illness IndexSocieties, Medical

Funding

  • Pfizer
  • GlaxoSmithKline
  • Parkinson's UK
  • National Institute of Neurological Disorders and Stroke
Citations
7,309
FWCI
28.41
field-weighted impact
References
13
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.